Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alnylam Pharmaceuticals has reported promising pre-clinical results related to its ALN-HTT program, an RNAi therapeutic drug-device combination for the treatment of Huntington's disease.
Subscribe to our email newsletter
The findings were the result of research partnership between Alnylam and Medtronic and supported by CHDI.
The results demonstrated that a small interfering RNA (siRNA) targeting huntingtin gene, when administered by intrastriatal infusion with convection-enhanced delivery (CED), results in widespread distribution of the siRNA.
The results also demonstrated significant silencing of the huntingtin mRNA throughout the striatum and administration of the RNAi therapeutic was well tolerated in these studies.
Alnylam research vice president Dinah Sah said the pre-clinical results extend earlier data on siRNA biodistribution in the central nervous system and degree and scope of therapeutic huntingtin gene silencing.